COCP (Cocrystal Pharma) 5-Year EBITDA Growth Rate : 27.90% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma 5-Year EBITDA Growth Rate?

Cocrystal Pharma's EBITDA per Share for the three months ended in Dec. 2024 was $-0.31.

During the past 3 years, the average EBITDA Per Share Growth Rate was 2.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 27.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 27.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cocrystal Pharma was 58.80% per year. The lowest was -256.00% per year. And the median was 4.40% per year.

Competitive Comparison of Cocrystal Pharma's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Cocrystal Pharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Cocrystal Pharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cocrystal Pharma (NAS:COCP) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Cocrystal Pharma 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cocrystal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

8CC:Germany

Address

19805 North Creek Parkway, Bothell, WA, USA, 98011

Website

https://www.cocrystalpharma.com

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Executives

Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al	director, 10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi	director, 10 percent owner	1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin	officer: Interim CFO	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale	officer: INTERIM CFO	1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers	officer: CHIEF MEDICAL OFFICER	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott	officer: GENERAL COUNSEL AND SECRETARY	1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler	director	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block	director
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027